India Plasma Fractionation Market Outlook, Size, Growth, Share, and Forecast 2032

The India plasma fractionation market is projected to grow from $326.3 million in 2021 to $470.6 million by 2030, with a 4.2% compound annual growth rate. The market analysis covers:

Key Market Segments:

• Products: Albumin, immunoglobulins, coagulation factors
• Applications: Immunology, neurology, hematology, critical care, pulmonology
• End-users: Hospitals, clinics, research organizations

Major Industry Players:

• Reliance Life Sciences
• Intas Pharmaceuticals
• Biocon Limited
• Bharat Serums and Vaccines (BSV)
• PlasmaGen BioSciences

Recent Developments:

• January 2025: USFDA clearance for Biocon's Malaysia insulin facility
• October 2024: Mankind Pharma acquired BSV for ₹13,768 crore
• September 2023: BSV announced ₹200 crore investment in Hyderabad facility

Market Drivers:

• Rising prevalence of immune deficiency disorders
• Growing demand for coagulation factors due to hemophilia cases
• COVID-19 impact increased demand for immunoglobulins

Key Challenges:

• Limited domestic plasma availability
• Blood wastage issues (approximately 6.5 lakh units annually)
• Restrictions on commercial apheresis collection in India

Footnotes

Fortune Business Insights - India Plasma Fractionation Market Size, Growth | Covid-19 Impact

https://www.fortunebusinessinsights.com/india-plasma-fractionation-market-106442